Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) presented a poster entitled “A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5” (the “Poster”), at the CNS Summit 2016 held in Boca Raton, Florida (the “EULAR Annual Meeting”).. The Poster was presented by Dr. Gregory Sullivan, M.D., Chief Medical Officer of the Company.
The foregoing description of the Poster is qualified in its entirety by reference to the Poster, a copy of which is filed as Exhibit 99.01 to, and is incorporated by reference in, this report.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.
